NCT04025437 is a Phase 2, PHASE3 clinical trial of Hepatectomy alone in Hepatocellular Carcinoma, sponsored by Guangxi Medical University.

Who is sponsoring NCT04025437?

NCT04025437 is sponsored by Guangxi Medical University.

What drugs are being tested in NCT04025437?

Interventions in NCT04025437: Hepatectomy alone, Neoadjuvant radiotherapy.

What condition does NCT04025437 study?

NCT04025437 studies Hepatocellular Carcinoma.

Is NCT04025437 still recruiting?

NCT04025437 is currently status unknown. Last updated 4 September 2019.

Last reviewed 2019-09-04 · How we verify

NCT04025437

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Radiotherapy for HCC Involving Type I PVTT

Status unknown Phase 2, PHASE3 Last updated 4 September 2019

What this trial tests

Phase 2, PHASE3 trial testing Hepatectomy alone in Hepatocellular Carcinoma in 214 participants. Status unknown.

Timeline

1 March 2019

Primary endpoint
30 December 2021

31 December 2021

Quick facts

Lead sponsor	Guangxi Medical University
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	214
Start date	1 March 2019
Primary completion	30 December 2021
Estimated completion	31 December 2021
Sites	1 location across China

Drugs / interventions tested

Hepatectomy alone
Neoadjuvant radiotherapy

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

Guangxi Medical University

Who can join

Adults 18 to 75, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The rate of patients with hepatocellular carcinoma (HCC) involving portal vein tumor thrombus (PVTT) is up to 50% in Guangxi province, China. Some of them will receive hepatic resection, especially those with type I or II PVTT. However, 5-years recurrence rate is up to 75% after surgery. Some retrospective studies found postoperative radiotherapy may reduce the rate of recurrence. Moreover, few retrospective studies also found neoadjuvant radiotherapy (PMID: 27317960) may improve overall survival for HCC patients involving type II/III PVTT. However, the safety and efficacy of neoadjuvant raidotherapy for HCC involving type I PVTT is unknown.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Clinical application of advances and innovation in radiation treatment of hepatocellular carcinoma.
Tong VJW, Shelat VG, Chao YK. · · 2021 · cited 9× · PMID 34988334

Verify or expand the search:

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Guangxi Medical University trials

Trials by the same sponsor.

NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT06851104 — A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence · Phase 2 · terminated
NCT05711823 — Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC · Phase 3 · unknown
NCT05910970 — Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation · Phase 3 · unknown
NCT06161272 — Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04025437 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangxi Medical University
Last refreshed: 4 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04025437.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing